MX2018003590A - Compuestos y metodos para la inhibicion de jak. - Google Patents

Compuestos y metodos para la inhibicion de jak.

Info

Publication number
MX2018003590A
MX2018003590A MX2018003590A MX2018003590A MX2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A MX 2018003590 A MX2018003590 A MX 2018003590A
Authority
MX
Mexico
Prior art keywords
methyl
compounds
ethyl
methods
inhibiting jak
Prior art date
Application number
MX2018003590A
Other languages
English (en)
Inventor
Marie Vasbinder Melissa
Birgitta Margareta Åstrand Annika
Patrick Grimster Neil
Kawatkar Sameer
Grant Kettle Jason
K Nilsson Magnus
Lys Ruston Linette
Su Qibin
James Winter-Holt Jon
Wu Dedong
Yang Wenzhan
Grecu Tudor
Mccabe James
Donald Woessner Richard
Edmundo Chuaqui Cluadio
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2018003590A publication Critical patent/MX2018003590A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos de fórmula (I), composiciones farmacéuticas que comprenden tales compuestos y métodos/usos para utilizar los mismos, por ejemplo, para tratar un trastorno relacionado con JAK, tal como cáncer, caquexia por cáncer o un trastorno inmune: (ver Fórmula) donde R1 es metilo o etilo; R2 se selecciona de metilo, etilo, metoxi y etoxi; R3 se selecciona de hidrógeno, cloro, flúor, bromo y metilo; R4 se selecciona de metilo, etilo y-CH2OCH3; R5 y R6 son cada uno individualmente metilo o hidrógeno; y R7 se selecciona de metilo, etilo,-(CH2)2OH y -(CH2)2OCH3, o una sal farmacéuticamente aceptable del mismo.
MX2018003590A 2015-09-25 2016-09-22 Compuestos y metodos para la inhibicion de jak. MX2018003590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562232629P 2015-09-25 2015-09-25
PCT/EP2016/072616 WO2017050938A1 (en) 2015-09-25 2016-09-22 Compounds and methods for inhibiting jak

Publications (1)

Publication Number Publication Date
MX2018003590A true MX2018003590A (es) 2018-11-29

Family

ID=56979589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003590A MX2018003590A (es) 2015-09-25 2016-09-22 Compuestos y metodos para la inhibicion de jak.

Country Status (18)

Country Link
US (5) US9714236B2 (es)
EP (2) EP4219482A1 (es)
JP (1) JP6767491B2 (es)
KR (1) KR20180058719A (es)
CN (4) CN111606893B (es)
AR (1) AR106138A1 (es)
AU (1) AU2016328764B2 (es)
BR (1) BR112018005833B1 (es)
CA (1) CA2995430C (es)
DK (1) DK3353168T3 (es)
ES (1) ES2956642T3 (es)
HK (1) HK1259422A1 (es)
MX (1) MX2018003590A (es)
PT (1) PT3353168T (es)
RU (1) RU2760359C2 (es)
TW (1) TWI740843B (es)
WO (1) WO2017050938A1 (es)
ZA (1) ZA201800782B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714236B2 (en) * 2015-09-25 2017-07-25 Astrazeneca Ab Compounds and methods for inhibiting JAK
BR112018074232A2 (pt) 2016-05-26 2019-03-06 Zeno Royalties & Milestones, LLC compostos inibidores de egfr
EP4219470A1 (en) * 2017-01-17 2023-08-02 Astrazeneca AB Jak1 selective inhibitors
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20210033474A (ko) * 2018-07-18 2021-03-26 아스트라제네카 아베 Jak 억제 화합물의 지나포에이트염
WO2020057669A1 (zh) * 2018-09-21 2020-03-26 上海轶诺药业有限公司 一类具有激酶抑制活性的芳香杂环类化合物
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
WO2020211839A1 (en) 2019-04-19 2020-10-22 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Jak1 selective kinase inhibitor
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN111961037B (zh) * 2020-09-17 2021-09-21 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
EP4253375A1 (en) * 2020-11-26 2023-10-04 Artivila (ShenZhen) Innovation Center, Ltd. Amide compound, pharmaceutical composition and use thereof
EP4304590A1 (en) * 2021-03-11 2024-01-17 Janssen Pharmaceutica NV Lorpucitinib for use in the treatment of jak mediated disorders
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676285A (zh) * 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
WO2007089768A2 (en) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
AU2007333394C1 (en) * 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2611793A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CA2815330A1 (en) * 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
KR20140019300A (ko) * 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
US20140045908A1 (en) * 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
MY165963A (en) * 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
JP6212107B2 (ja) 2012-03-29 2017-10-11 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 脱毛障害を処置するための方法
US9714236B2 (en) * 2015-09-25 2017-07-25 Astrazeneca Ab Compounds and methods for inhibiting JAK

Also Published As

Publication number Publication date
ZA201800782B (en) 2018-12-19
CN111606893A (zh) 2020-09-01
CN111848586A (zh) 2020-10-30
CN111606893B (zh) 2021-05-04
US20210078981A1 (en) 2021-03-18
JP2018529770A (ja) 2018-10-11
EP3353168B1 (en) 2023-08-30
JP6767491B2 (ja) 2020-10-14
HK1259422A1 (zh) 2019-11-29
US20220119372A1 (en) 2022-04-21
US11247983B2 (en) 2022-02-15
US20190092760A1 (en) 2019-03-28
US20170320857A1 (en) 2017-11-09
CA2995430C (en) 2023-07-11
BR112018005833A2 (pt) 2018-10-16
TW201730186A (zh) 2017-09-01
ES2956642T3 (es) 2023-12-26
CA2995430A1 (en) 2017-03-30
US9714236B2 (en) 2017-07-25
CN111848586B (zh) 2024-05-03
AU2016328764B2 (en) 2020-07-09
US20170088543A1 (en) 2017-03-30
DK3353168T3 (da) 2023-10-02
EP4219482A1 (en) 2023-08-02
EP3353168A1 (en) 2018-08-01
US10654835B2 (en) 2020-05-19
RU2018112993A (ru) 2019-10-28
CN108368091B (zh) 2020-08-11
AR106138A1 (es) 2017-12-13
CN111646980B (zh) 2021-08-27
TWI740843B (zh) 2021-10-01
AU2016328764A1 (en) 2018-02-22
US10167276B2 (en) 2019-01-01
CN108368091A (zh) 2018-08-03
KR20180058719A (ko) 2018-06-01
CN111646980A (zh) 2020-09-11
WO2017050938A1 (en) 2017-03-30
BR112018005833B1 (pt) 2023-10-10
PT3353168T (pt) 2023-09-20
RU2760359C2 (ru) 2021-11-24
RU2018112993A3 (es) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2018003590A (es) Compuestos y metodos para la inhibicion de jak.
MX2018012174A (es) Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
GEP20227428B (en) Heterocyclic compounds as immunomodulators
MX2016011992A (es) Derivados de piperidina-diona.
PH12016501440A1 (en) Novel heterocyclic compounds
MY188114A (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
NZ718055A (en) Substituted pyrimidine bmi-1 inhibitors
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
PH12017501825A1 (en) Bicyclic quinazolinone derivatives
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
NZ708909A (en) Substituted reverse pyrimidine bmi-1 inhibitors
MX365590B (es) Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
PH12018501849A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
AU2018253590A1 (en) Imidazopyridazine compounds
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2019013194A (es) Procedimientos para preparar compuestos de tipo oxatiazina.
MX2022000376A (es) Aminopirimidinas como inhibidores de alk.
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2016008909A (es) Compuestos de isopropil triazolo piridina.

Legal Events

Date Code Title Description
FG Grant or registration